A Phase 2 interventional study of Durvalumab + Oleclumab and Durvalumab in Stage III Non-small Cell Lung Cancer and Unresectable, sponsored by MedImmune LLC. Completed at 73 sites in 9 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 25th largest by enrollment, is one of 8 that started in 2018, is one of 58 in phase 2, and was the 36th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 189 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 26 open now, 79 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 60th largest by enrollment of the 138 interventional ones that give a count, is one of 20 that started in 2018, is one of 39 in phase 2, and was the 115th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 210 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.
Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
durvalumab IV
Drug: Durvalumab
durvalumab IV and oleclumab IV
Drug: Durvalumab + Oleclumab
durvalumab IV and monalizumab IV
Drug: Durvalumab + Monalizumab
Drug pages: Durvalumab · Oleclumab
Durvalumab + Oleclumab
Also known as: Durvalumab (MEDI-4736), Oleclumab (MEDI-9447)
Durvalumab
Also known as: Durvalumab (MEDI-4736)
Drug pages: Durvalumab · Monalizumab
Durvalumab + Monalizumab
Also known as: Durvalumab (MEDI-4736), Monalizumab (IPH2201)
Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
ORR was defined as the percentage of participants with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.
Time frame: ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint
Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents
The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events
Time frame: From time of signature of informed consent up to 15 months post the first dose of study treatment
Presence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents
The secondary endpoint of safety as assessed by the presence of Grade 3 or 4 clinical laboratory toxicities (based on NCI-CTCAE v5.0) in chemistry and hematology values
Time frame: From baseline up to 15 months post the first dose of study treatment
Presence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents
The secondary endpoint of safety as assessed by the presence of abnormal vital signs reported as adverse events
Time frame: From baseline up to 15 months post the first dose of study treatment
Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only participants who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR
Time frame: Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).
Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
Disease control rate (DCR) was defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD (maintained for ≥ 16 weeks) based on RECIST v1.1.
Time frame: Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).
Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
PFS was defined as the time from randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first
Time frame: Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).
Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
PFS-12 was defined as the percentage of participants who were alive and progression free at 12 months after randomization.
Time frame: PFS rate at 12 months after randomization.
Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
OS was defined as the time from the date of randomization until death due to any cause.
Time frame: From time of randomization until death due to any cause. Assessed through the database cutoff date of 18-Jul-2023).
Pharmacokinetics of Durvalumab Alone and in Combination With Novel Agents
Geometric mean serum concentrations of durvalumab (μg/mL) were reported for each time point where data warrant, as appropriate.
Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Pharmacokinetics of Novel Agents in Combination With Durvalumab
Geometric mean serum concentrations of oleclumab (μg/mL) and monalizumab (μg/mL) were reported for each time point where data warrant, as appropriate.
Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Presence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.
Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Presence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.
Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
The first participant was randomized into the study on 3 January 2019 and the last participant was randomized on 6 July 2020.
| Milestone | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Started | 67 | 60 | 62 |
| Completed | 21 | 29 | 30 |
| Not completed | 46 | 31 | 32 |
| Withdrew: Death | 27 | 23 | 24 |
| Withdrew: Lost to follow-up | 6 | 2 | 1 |
| Withdrew: Withdrawal by subject | 10 | 4 | 6 |
| Withdrew: Progressive disease | 2 | 1 | 0 |
| Withdrew: Not treated | 1 | 1 | 1 |
ORR was defined as the percentage of participants with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.
| Percentage of Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents | 23.9 (14.3 to 35.9) | 35.0 (23.1 to 48.4) | 40.3 (28.1 to 53.6) |
The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events
| Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Participants with any TEAEs | 65 | 57 | 61 |
| Participants with any serious TEAEs | 23 | 20 | 17 |
The secondary endpoint of safety as assessed by the presence of Grade 3 or 4 clinical laboratory toxicities (based on NCI-CTCAE v5.0) in chemistry and hematology values
| Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Participants with any Grade 3 or 4 Alanine Aminostransferase (U/L) toxicities | 1 | 0 | 0 |
| Participants with any Grade 3 or 4 Albumin (g/dL) toxicities | 2 | 0 | 0 |
| Participants with any Grade 3 or 4 Amylase (U/L) toxicities | 1 | 0 | 2 |
| Participants with any Grade 3 or 4 Aspartate Aminotransferase (U/L) toxicities | 1 | 0 | 1 |
| Participants with any Grade 3 or 4 Creatinine (mg/dL) toxicities | 1 | 0 | 0 |
| Participants with any Grade 3 or 4 Creatinine Clearance Rate (mL/min) toxicities | 2 | 1 | 0 |
| Participants with any Grade 3 or 4 Gamma Glutamyl Transferase (U/L) toxicities | 1 | 0 | 0 |
| Participants with any Grade 3 or 4 Hyperkalemia (mEq/L) toxicities | 0 | 0 | 2 |
| Participants with any Grade 3 or 4 Hypokalemia (mEq/L) toxicities | 1 | 0 | 1 |
| Participants with any Grade 3 or 4 Hypocalcemia (corrected) (mg/dL) toxicities | 1 | 0 | 0 |
| Participants with any Grade 3 or 4 Hypernatremia (mEq/L) toxicities | 1 | 2 | 1 |
| Participants with any Grade 3 or 4 Lipase (U/L) toxicities | 1 | 4 | 2 |
| Participants with any Grade 3 or 4 Hemoglobin increased (g/dL) toxicities | 3 | 0 | 0 |
| Participants with any Grade 3 or 4 Lymphocyte count increased (10^3/uL) toxicities | 19 | 11 | 11 |
| Participants with any Grade 3 or 4 Platelet count decreased (10^3/uL) toxicities | 1 | 0 | 0 |
The secondary endpoint of safety as assessed by the presence of abnormal vital signs reported as adverse events
| Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Hypertension | 3 | 3 | 0 |
| Hypotension | 2 | 0 | 3 |
| Palpitations | 0 | 0 | 1 |
| Pyrexia | 6 | 8 | 10 |
| Tachycardia | 1 | 2 | 2 |
The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only participants who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR
| Months | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents | NA (14.1 to NA) | 29.9 (17.1 to NA) | 23.0 (10.2 to NA) |
Disease control rate (DCR) was defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD (maintained for ≥ 16 weeks) based on RECIST v1.1.
| Percentage of Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents | 58.2 (45.5 to 70.2) | 80.0 (67.7 to 89.2) | 79.0 (66.8 to 88.3) |
PFS was defined as the time from randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first
| Months | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents | 7.3 (4.0 to 13.8) | 21.1 (10.4 to 30.9) | 19.8 (13.6 to 31.3) |
PFS-12 was defined as the percentage of participants who were alive and progression free at 12 months after randomization.
| Percentage of Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents | 37.6 (24.7 to 50.4) | 63.5 (49.2 to 74.7) | 73.2 (59.6 to 82.9) |
OS was defined as the time from the date of randomization until death due to any cause.
| Months | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents | 40.9 (22.6 to NA) | NA (31.9 to NA) | NA (31.3 to NA) |
Geometric mean serum concentrations of durvalumab (μg/mL) were reported for each time point where data warrant, as appropriate.
| Micrograms per milliliter | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| Cycle 1 Day 1: End of Infusion | 318.0 ± 199.6 | 277.4 ± 316.1 | 223.7 ± 1272 |
| Cycle 2 Day 1: Pre-Dose | 59.7 ± 58.6 | 68.0 ± 49.9 | 74.3 ± 40.7 |
| Cycle 7 Day 1: Pre-Dose | 151.6 ± 37.7 | 127.9 ± 66.4 | 176.5 ± 45.6 |
| Cycle 11 Day 1: Pre-Dose | 156.7 ± 50.0 | 146.5 ± 91.3 | 172.4 ± 40.4 |
Geometric mean serum concentrations of oleclumab (μg/mL) and monalizumab (μg/mL) were reported for each time point where data warrant, as appropriate.
| Micrograms per milliliter | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|
| Cycle 1 Day 1: End of Infusion | 581.6 ± 210.5 | 160.0 ± 286.4 |
| Cycle 2 Day 1: Pre-Dose | 216.4 ± 58.6 | 102.6 ± 39.2 |
| Cycle 7 Day 1: Pre-Dose | 124.5 ± 109.0 | 194.5 ± 33.8 |
| Cycle 11 Day 1: Pre-Dose | 132.0 ± 166.8 | 196.2 ± 48.7 |
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.
| Participants | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|---|
| ADA positive at any visit (ADA prevalence) | 3 | 1 | 2 |
| Treatment-emergent ADA positive (ADA incidence) | 1 | 0 | 0 |
| Treatment-boosted ADA | 0 | 0 | 0 |
| Treatment-induced ADA (positive post-baseline only) | 1 | 0 | 0 |
| ADA positive at baseline only | 2 | 1 | 2 |
| ADA positive post-baseline and positive at baseline | 0 | 0 | 0 |
| Persistently positive | 1 | 0 | 0 |
| Transiently positive | 0 | 0 | 0 |
ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.
| Participants | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) |
|---|---|---|
| ADA positive at any visit (ADA prevalence) | 0 | 1 |
| Treatment-emergent ADA positive (ADA incidence) | 0 | 1 |
| Treatment-boosted ADA | 0 | 0 |
| Treatment-induced ADA (positive post-baseline only) | 0 | 1 |
| ADA positive at baseline only | 0 | 0 |
| ADA positive post-baseline and positive at baseline | 0 | 0 |
| Persistently positive | 0 | 0 |
| Transiently positive | 0 | 1 |
Collected over AEs and SAEs were collected from time of signature of informed consent up to 15 months post the first dose of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab Monotherapy | 27/66 (40.9%) | 23/66 (34.8%) | 61/66 (92.4%) |
| Durvalumab + Oleclumab | 23/59 (39%) | 20/59 (33.9%) | 52/59 (88.1%) |
| Durvalumab + Monalizumab | 24/61 (39.3%) | 17/61 (27.9%) | 58/61 (95.1%) |
| Event | Durvalumab Monotherapy | Durvalumab + Oleclumab | Durvalumab + Monalizumab |
|---|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/66 | 6/59 | 2/61 |
| PneumoniaInfections and infestations | 5/66 | 4/59 | 0/61 |
| Radiation pneumonitisInjury, poisoning and procedural complications | 1/66 | 2/59 | 0/61 |
| SeizureNervous system disorders | 2/66 | 0/59 | 0/61 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/66 | 0/59 | 1/61 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/66 | 1/59 | 0/61 |
| PyrexiaGeneral disorders | 0/66 | 1/59 | 1/61 |
| Sudden deathGeneral disorders | 0/66 | 1/59 | 0/61 |
| AppendicitisInfections and infestations | 0/66 | 1/59 | 0/61 |
| Enterocolitis infectiousInfections and infestations | 0/66 | 1/59 | 0/61 |
| Event | Durvalumab Monotherapy | Durvalumab + Oleclumab | Durvalumab + Monalizumab |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 11/66 | 19/59 | 26/61 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 17/66 | 15/59 | 14/61 |
| PruritusSkin and subcutaneous tissue disorders | 7/66 | 10/59 | 15/61 |
| AstheniaGeneral disorders | 10/66 | 11/59 | 15/61 |
| HypothyroidismEndocrine disorders | 10/66 | 8/59 | 13/61 |
| DiarrhoeaGastrointestinal disorders | 7/66 | 8/59 | 13/61 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/66 | 10/59 | 11/61 |
| RashSkin and subcutaneous tissue disorders | 6/66 | 9/59 | 8/61 |
| ConstipationGastrointestinal disorders | 10/66 | 4/59 | 2/61 |
| PyrexiaGeneral disorders | 6/66 | 7/59 | 9/61 |
The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group
| Age, Continuous(years) | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) | Total |
|---|---|---|---|---|
| Mean | 65.5 ± 8.9 | 63.8 ± 9.5 | 64.4 ± 9.2 | 64.6 ± 9.2 |
| Sex: Female, Male(Participants) | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) | Total |
|---|---|---|---|---|
| Female | 22 | 18 | 20 | 60 |
| Male | 45 | 42 | 42 | 129 |
| Ethnicity (NIH/OMB)(Participants) | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 2 | 8 |
| Not Hispanic or Latino | 63 | 56 | 59 | 178 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 5 | 4 | 5 | 14 |
| Black or African American | 1 | 5 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| White | 57 | 47 | 55 | 159 |
| Other | 1 | 2 | 0 | 3 |
| Missing | 2 | 1 | 0 | 3 |
| Region of Enrollment(Participants) | Control Arm (Durvalumab Monotherapy) | Arm A (Durvalumab + Oleclumab) | Arm B (Durvalumab + Monalizumab) | Total |
|---|---|---|---|---|
| Canada | 3 | 2 | 1 | 6 |
| France | 15 | 19 | 5 | 39 |
| Hong-Kong | 1 | 2 | 3 | 6 |
| Italy | 0 | 3 | 3 | 6 |
| Portugal | 3 | 0 | 3 | 6 |
| Spain | 19 | 12 | 22 | 53 |
| Taiwan | 1 | 0 | 1 | 2 |
| United States | 25 | 22 | 24 | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2018 to primary completion in Jul 2023, 54 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 54 months is above that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Oleclumab · Monalizumab
Carcinoma, Non-Small-Cell Lung →